Provided by Tiger Trade Technology Pte. Ltd.

Merck

147.53
-0.9300-0.63%
Pre-market: 148.260.7300+0.49%06:02 EDT
Volume:8.55M
Turnover:1.26B
Market Cap:363.98B
PE:115.91
High:149.41
Open:148.96
Low:147.18
Close:148.46
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:1.04
T/O Rate:0.35%
Dividend:3.32
Dividend Rate:2.25%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.68
PE(LYR):20.27

Loading ...

Merck Price Target Raised to $161.00/Share from $127.00 by Leerink Partners

Dow Jones
·
17 hours ago

Leerink Partners Adjusts Price Target on Merck & Co. to $161 From $127, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

Merck & Co Inc : Leerink Partners Raises Target Price to $161 from $127

THOMSON REUTERS
·
Yesterday

Merck price target raised to $161 from $127 at Leerink

TIPRANKS
·
Yesterday

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Yesterday

Merck CEO Davis, R&D Head Li to Speak at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 08

Guggenheim Adjusts Price Target on Merck & Co. to $170 From $146, Maintains Buy Rating

MT Newswires Live
·
Sep 08

Merck & Co Inc : Guggenheim Raises Target Price to $170 from $146

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Merck & Company (MRK)

TIPRANKS
·
Sep 08

Merck KGaA (0O14) Gets a Hold from Barclays

TIPRANKS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 08

Merck & Co. Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Merck Price Target Raised to $170.00/Share from $150.00 by Wells Fargo

Dow Jones
·
Sep 04

Dow Jones Top Company Headlines at 9 am ET: EQT to Buy Insurance Broker McGill in $2 Billion Deal | Tesla-Challenging ...

Dow Jones
·
Sep 04

Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating

MT Newswires Live
·
Sep 04

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results

TIPRANKS
·
Sep 04

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Jefferies Reaffirms Their Hold Rating on Merck KGaA (0O14)

TIPRANKS
·
Sep 03

Novartis Signs Deal Worth up to $3.2 Billion for Alteogen's Drug Delivery Technology

Reuters
·
Sep 02

Merck CFO Litchfield, R&D Chief Li to Speak at Wells Fargo Healthcare Conference

Reuters
·
Sep 02